Ipamorelin vs MK-677: Selectivity, Side Effects and Evidence Compared

Feature	Ipamorelin	MK-677 (Ibutamoren)
Chemical class	Synthetic pentapeptide (5 amino acids)	Non-peptide spiropiperidine small molecule
Developer	Novo Nordisk (1994), later Helsinn Therapeutics	Merck & Co (1990s)
Primary receptor	GHS-R1a (ghrelin receptor) – selective	GHS-R1a (ghrelin receptor) – broader activity
Administration	Subcutaneous injection	Oral capsule (60%+ bioavailability)
Half-life	Approximately 2 hours	Approximately 24 hours
Effect on cortisol/prolactin	No significant effect (Raun 1998)	Mild cortisol elevation possible
Appetite stimulation	Minimal	Significant (ghrelin mechanism)
Longest published human study	Phase 2 for postoperative ileus (Helsinn)	2-year RCT in healthy older adults (Nass 2008)
FDA status (2026)	PCAC rejected October 2024, no approved product	PCAC rejected October 2024, never on Category 2 list
WADA status	S2 – prohibited at all times	S2.2.4 – prohibited at all times
Commonly stacked with	CJC-1295 (no DAC) or sermorelin	Typically used alone (oral)

Both ipamorelin and MK-677 activate the same receptor – the growth hormone secretagogue receptor GHS-R1a on pituitary somatotroph cells – but they do it with fundamentally different selectivity and pharmacological profiles. Ipamorelin is a five-amino-acid peptide that binds GHS-R1a and triggers growth hormone release without measurably affecting cortisol, prolactin, or ACTH levels. This was the defining finding of the Raun 1998 paper in the European Journal of Endocrinology that first characterised ipamorelin as “the first selective growth hormone secretagogue,” distinguishing it from earlier GH-releasing peptides like GHRP-6 and GHRP-2 that caused broader hormonal disruption.

MK-677 is not a peptide at all. It is a small organic molecule – a spiropiperidine compound – that mimics ghrelin’s action at the receptor. Because it replicates ghrelin’s broader pharmacological footprint rather than just one aspect of it, MK-677 activates appetite pathways (ghrelin is the primary hunger hormone), can mildly elevate cortisol, and affects insulin sensitivity in ways that ipamorelin does not. Its oral bioavailability exceeding 60% is the key practical advantage – this is a compound that can be taken as a daily capsule rather than requiring subcutaneous injection.

The signalling pathway distinction matters for combination protocols. Ipamorelin works through the Gq/PLC/IP3 pathway at pituitary somatotroph cells. GHRH analogs like CJC-1295 and sermorelin work through the Gs/cAMP/PKA pathway. When combined, these dual signals produce GH release greater than the sum of individual responses – a synergistic effect. This is why ipamorelin is almost always prescribed in combination with a GHRH analog rather than alone. MK-677, by contrast, is typically used as a standalone oral agent.

The bottom line: Ipamorelin produces selective, clean GH pulses without hormonal side effects, while MK-677 produces sustained, broader GH-axis activation that also drives appetite, can affect cortisol, and impairs insulin sensitivity – the trade-off for oral convenience.

MK-677 has the substantially deeper evidence base, with multiple randomised controlled trials spanning different indications and durations up to two years. Ipamorelin’s published clinical evidence is considerably more limited, despite its selectivity advantage.

MK-677 key trials

The landmark study is Nass et al. 2008, published in the Annals of Internal Medicine – a two-year, double-blind, randomised, placebo-controlled trial enrolling 65 healthy adults aged 60-81. At 25 mg daily, MK-677 increased GH levels 1.8-fold and IGF-1 levels 1.5-fold to ranges seen in healthy young adults. Participants gained an average of 1.1 kg fat-free mass over 12 months. However, the study found no improvement in strength or physical function, and fasting glucose increased by approximately 0.3 mmol/L with measurable decline in insulin sensitivity.

Other notable Merck-sponsored studies include Murphy 1998 (demonstrated reversal of diet-induced catabolism over 8 weeks with 3 kg fat-free mass gain), Murphy 2001 (292 postmenopausal osteoporotic women, examining MK-677 alone and combined with alendronate for bone mineral density), and Svensson 1998 (increased bone formation markers in obese young males). Sevigny 2008 tested MK-677 for Alzheimer’s disease progression in 563 patients and found no clinical effect, effectively closing that investigational pathway.

Ipamorelin key trials

Ipamorelin’s published evidence centres on the Raun 1998 characterisation study and Phase 2 work by Helsinn Therapeutics for postoperative ileus – a condition where the intestines temporarily stop functioning after surgery. The ileus trials leveraged ipamorelin’s prokinetic properties (its ghrelin receptor activation can stimulate gastrointestinal motility) rather than its GH-releasing effects. Helsinn discontinued the programme, and ipamorelin has never progressed beyond Phase 2 for any indication. The key pharmacological data point remains the selectivity finding: GH release without cortisol, prolactin, or ACTH elevation.

The bottom line: MK-677 has the deeper clinical evidence base including a two-year RCT showing fat-free mass gains but no strength improvement and worsened insulin sensitivity, while ipamorelin’s evidence is limited to Phase 2 data but its selectivity profile is confirmed as cleaner than any other GH secretagogue.

Both ipamorelin and MK-677 were reviewed at the same PCAC meeting on October 29, 2024, and both were voted against for inclusion on the 503A Bulks List. Neither compound has ever been FDA-approved. However, their regulatory trajectories differ in important ways.

Ipamorelin was placed on the FDA Category 2 restricted list in September 2023 alongside other peptides, then removed in September 2024 when its nomination was withdrawn. After the PCAC rejection, it has no authorised compounding pathway. Whether it is included in the February 2026 Kennedy reclassification announcement remains subject to formal publication – see the reclassification tracker for current status.

MK-677 was never placed on the Category 2 restricted list, which means it was never formally restricted from compounding in the same way as ipamorelin. Some compounding pharmacies continued to offer MK-677 through the period when peptides were most heavily restricted. Its PCAC rejection means the committee did not recommend adding it to the 503A Bulks List, but MK-677’s status as a non-peptide small molecule gives it a somewhat different regulatory profile. It is not DEA-scheduled and not a controlled substance. For full context on the category system and what it means for compounding access, see the dedicated explainer.

Both compounds are prohibited by WADA under Section S2 of the Prohibited List as growth hormone secretagogues, banned both in-competition and out-of-competition. Neither should be used by anyone subject to anti-doping testing.

Jurisdiction	Ipamorelin	MK-677
United States	PCAC rejected, was on Category 2, no approved product	PCAC rejected, never on Category 2, available via some pharmacies
United Kingdom	Not controlled, no approved product, RUO available	Not controlled, no approved product, sold as research chemical
Australia	Schedule 4 (prescription only)	Schedule 4 (prescription only)
WADA	S2 – prohibited at all times	S2.2.4 – prohibited at all times

For country-specific legal frameworks in detail, see the jurisdiction guides for the United States, United Kingdom, and Australia.

The bottom line: MK-677 has slightly easier access in 2026 because it was never placed on the Category 2 restricted list, while ipamorelin’s compounding pathway remains blocked pending formal resolution of the reclassification process.

The side effect comparison is where ipamorelin’s selectivity advantage translates most clearly into a practical difference. Ipamorelin’s published adverse effects are limited to injection site reactions and mild, transient headaches. No significant impact on cortisol, prolactin, appetite, or glucose homeostasis has been documented in clinical studies. This clean side effect profile is a direct consequence of its highly selective receptor binding – it activates GHS-R1a at the pituitary without triggering the broader downstream effects that less selective ghrelin mimetics produce.

MK-677’s side effect profile is more complex and better documented thanks to its more extensive trial programme. The Nass 2008 two-year trial provides the most comprehensive data. At 25 mg daily, the principal concerns are appetite stimulation (a direct, on-target effect of ghrelin receptor activation that can be substantial, particularly in the first 4-6 weeks), fluid retention presenting as peripheral oedema and puffiness, and fasting glucose elevation of approximately 0.3 mmol/L with decline in insulin sensitivity. The glucose effect is clinically meaningful for anyone with prediabetes or metabolic risk factors.

A further practical consideration: MK-677’s 24-hour half-life means side effects persist for the full day and take several days to clear completely after discontinuation. Ipamorelin’s 2-hour half-life means adverse effects, should they occur, resolve within hours. This same principle applies to overcorrection – if GH and IGF-1 are elevated beyond intended levels, course-correcting with ipamorelin is far faster.

The bottom line: Ipamorelin has the cleaner side effect profile based on its selectivity, while MK-677’s appetite stimulation, fluid retention, and glucose effects are well-documented trade-offs for oral convenience and sustained GH elevation.

The choice between ipamorelin and MK-677 comes down to a clear trade-off between selectivity and convenience.

Ipamorelin’s strengths are its clean hormonal profile (no cortisol, prolactin, or appetite effects), its ability to be combined synergistically with GHRH analogs for amplified GH response, and its short half-life allowing precise timing and rapid resolution of effects. The trade-off is that it requires subcutaneous injection and is most effective when stacked with a GHRH analog such as CJC-1295 or sermorelin, adding complexity and cost. Its Phase 2-level evidence base is thinner than MK-677’s.

MK-677’s strengths are oral administration (eliminating the barrier of daily injections), continuous GH and IGF-1 elevation from a single daily dose, a deeper clinical evidence base with published data spanning body composition, bone health, catabolism, and Alzheimer’s disease, and slightly easier regulatory access in 2026. The trade-offs are significant appetite stimulation, fluid retention, glucose dysregulation, and broader hormonal activation that ipamorelin avoids.

It is also worth noting what the Nass 2008 trial actually showed at the outcome level: 1.1 kg fat-free mass gain over 12 months with no improvement in strength or physical function. Some of the fat-free mass gain may reflect intracellular water rather than new contractile tissue. This is the most rigorous outcome data available for either compound, and it sets realistic expectations for what GH secretagogue therapy can and cannot achieve.

For anyone sourcing either compound outside regulated pharmacy channels, product quality verification is essential. See the vendor evaluation guide and the COA reading guide for assessment frameworks.

Why is MK-677 grouped with peptides when it is not actually a peptide?

MK-677 is a non-peptide small organic molecule that targets the same ghrelin receptor as peptide secretagogues. It gets grouped with peptides because it is sold through the same vendors, prescribed by the same clinics, and produces overlapping effects. Structurally, it has more in common with conventional oral pharmaceuticals than with ipamorelin or any other peptide. This classification confusion matters for regulatory purposes: MK-677 was not included in the FDA’s Category 2 peptide restrictions precisely because it is not a peptide.

Can MK-677’s appetite side effect be managed or does it persist?

The appetite stimulation is an on-target pharmacological effect – MK-677 mimics ghrelin, which is the primary hunger hormone. Most clinical and community observations suggest the effect is strongest in the first 4-6 weeks and diminishes for many individuals as the body adapts. It does not disappear entirely for all users. The appetite effect is dose-dependent, and lower doses reduce it while preserving most of the IGF-1 elevation. This is one reason ipamorelin is preferred by those wanting GH stimulation without caloric intake challenges.

If Merck developed MK-677 with extensive trials, why did they never seek FDA approval?

Merck’s decision appears to reflect a commercial and clinical calculation rather than a single safety event. The Nass 2008 trial showed fat-free mass gains without functional improvement – a result that would have been difficult to build an FDA approval case around. The Sevigny 2008 Alzheimer’s trial showed no clinical effect, closing another potential indication. Combined with the glucose and insulin sensitivity concerns, the benefit-risk profile did not support the investment required for a full regulatory submission. The hip fracture trial by Adunsky in 2011 also failed to demonstrate clinical benefit. Cumulatively, MK-677 consistently raised GH and IGF-1 but failed to translate that into the kind of hard clinical endpoints the FDA requires for approval.

Does anamorelin’s FDA approval tell us anything about ipamorelin’s potential?

Anamorelin (brand name Adlumiz) is a GH secretagogue that received FDA approval for cancer-related cachexia based on the ROMANO trials. It demonstrates that the GH secretagogue mechanism can clear the FDA approval bar when targeted at a specific, measurable clinical indication with clear endpoints. Ipamorelin was developed for postoperative ileus – a different indication leveraging its prokinetic properties rather than its GH effects. The comparison shows that pathway matters: GH secretagogues need a well-defined clinical indication with measurable outcomes, not just a demonstration that they raise GH levels. Ipamorelin’s selectivity advantage over anamorelin would only matter if it were being developed for the same indication with the same endpoint structure.